We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Infectious Diseases

Recombinant Herpes Zoster Vaccine Demonstrates Safety and Non-Inferiority in Patients with Autoimmune Rheumatic Diseases

MedXY Editorial Team•Feb 15, 2026•Infectious Diseases
immunosuppressionrheumatology

High-Level Highlights

1. Non-Inferior Flare Risk

The study successfully met its primary endpoint, demonstrating that the recombinant zoster vaccine (RZV) is non-inferior to placebo regarding the risk of disease flares in patients with autoimmune rheumatic diseases (AIRD). The flare rate was 14% in the vaccine group compared to 15% in the placebo group.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

HBV-Induced Immunosuppressive Macrophages: Metabolic and Epigenetic Pathways Driving Chronic Hepatitis B PersistenceThis article reviews recent evidence on how HBV manipulates monocyte-to-macrophage differentiation through metabolic and epigenetic reprogramming, facilitating immunosuppression and chronic infection.Sep 21, 2026HPV-Associated Anal Dysplasia in Solid Organ Transplant Recipients: Unraveling Transplant-Specific Mucosal Immune DysfunctionSolid organ transplant recipients have increased risk of HPV-driven anal dysplasia and cancer due to unique immune alterations from immunosuppression. This article explores the transplant-specific immune dysfunction underlying persistent HPSep 5, 2026Reevaluating Calcineurin Inhibitor Use in Identical Twin Kidney Transplants: Are We Overmedicating?Despite identical immunogenetic makeup, half of kidney transplant recipients from identical twins remain on calcineurin inhibitors, with no demonstrable benefit in rejection reduction or graft survival over 25 years, calling for critical reSep 4, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Belatacept and Sirolimus Show Promise as Safer Immunosuppression in Islet Transplantation for Type 1 Diabetes
A multi-centre phase 2 study demonstrates that belatacept combined with sirolimus achieves superior islet transplant outcomes with better renal preservation compared to conventional tacrolimus-based therapy in type 1 diabetes patients.
Aug 18, 2026
Targeting the IL-17/NGAL/NETs/ITGA5 Axis: A Novel Strategy to Overcome Immunosuppression and Fibroblast Reprogramming in Pancreatic CancerThis study unravels how tumour-derived NGAL induces NETs that reprogram fibroblast subtypes via ITGA5, promoting immunosuppression and tumour progression in pancreatic ductal adenocarcinoma, suggesting combinatorial therapies to enhance immJul 20, 2026
Unveiling the Role of IL-10-Neutralising Autoantibodies in Pediatric-Onset Inflammatory Bowel Disease: Prevalence, Persistence, and Clinical ImplicationsThis study reveals that IL-10-neutralising autoantibodies occur in 2.1% of pediatric IBD cases without monogenic causes, persist over years, and may define a distinct clinical subgroup with specific therapeutic needs.Jul 10, 2026